F2
EstablishedF2/prothrombin G20210A is one of five classic inherited thrombophilias, tested selectively rather than universally.
This gene makes a key clotting protein, and one specific genetic variant modestly raises the risk of blood clots. Testing isn't recommended for everyone — only for younger patients with unusual or recurrent clots, or strong family history, since the result rarely changes treatment on its own.
F2 encodes prothrombin, the precursor to thrombin, the central enzyme of the coagulation cascade. A specific mutation in this gene, prothrombin G20210A, is one of the five classic inherited thrombophilias that increase venous thromboembolism (VTE) risk.
Carriers of the prothrombin G20210A mutation have increased plasma prothrombin levels and roughly 2-3x increased VTE risk; the mutation has also been studied in relation to arterial events like myocardial infarction and stroke in younger patients, with more modest and inconsistent associations.
Diagnosed via genetic testing (not a clotting activity assay, since this is a gain-of-function mutation rather than a deficiency); current clinical guidelines discourage universal thrombophilia testing, recommending it only when a positive result would meaningfully change management or benefit family members.
Testing is generally reserved for young patients with unprovoked VTE, recurrent events, thrombosis at unusual sites, or a strong family history; per 2021 ACCP guidelines, thrombophilia status (including this mutation) is no longer used to guide anticoagulation duration decisions the way it was in older guidance.
Current guidelines have moved away from using thrombophilia status to guide anticoagulation duration decisions.
- Journal of the American Association of Nurse Practitioners. (2026). Inherited thrombophilias: Genetics and testing.
- ASH. VTE Guidelines: Thrombophilia Testing.